Pheochromocytoma of the adrenal gland secreting catecholamines is a relatively rare endocrinological cause of secondary arterial hypertension, usually developing in people aged between 40 and 50, more often in women than in men. Each accidentally diagnosed lesion in adrenal glands is an incidentalom0a. Incidentalomas are most commonly benign tumours: adenomas, adipomas and angiomas; less often they are of a malignant or metastatic character. Establishing the character of the lesion and its hormonal activity is of crucial diagnostic significance. Diagnostics of pheochromocytoma covers marking the urine output of catecholamines and their metabolites, as well as marking serum amine concentration. Possible treatment of hormonally active lesions includes their surgical removal. This thesis presents the case of a young female suffering from arterial hypertension for several years, including organ complications, who was diagnosed with pheochromocytoma selectively secreting dopamine.

Download full-text PDF

Source

Publication Analysis

Top Keywords

pheochromocytoma adrenal
8
adrenal gland
8
selectively secreting
8
secreting dopamine
8
arterial hypertension
8
pheochromocytoma
4
gland selectively
4
dopamine case
4
case report
4
report pheochromocytoma
4

Similar Publications

Background: Several cases of pheochromocytoma presenting with hypertensive crises after anesthesia induction, possibly caused by rocuronium injection, have been reported. Rocuronium has two compositions: rocuronium bromide (RB) in sodium acetate hydrate/acetic acid buffer solution (acetic acid vehicle) and RB in glycine/hydrochloric acid buffer solution (hydrochloric acid vehicle). This study assessed the effect of rocuronium composition on the release of catecholamine from PC-12 rat adrenal pheochromocytoma cells.

View Article and Find Full Text PDF

Pheochromocytoma (PHEO) currently is considered to be malignant due to metastatic potential. One of the most common familial forms of PHEO is multiple endocrine neoplasia syndrome (MEN) type 2. The penetrance of PHEO in MEN2 syndrome is up to 50% of cases.

View Article and Find Full Text PDF

Extra-adrenal pheochromocytomas are rare neuroendocrine tumors originating outside the adrenal glands and can pose significant diagnostic challenges due to their variable presentations. This report highlights a case of an extra-adrenal pheochromocytoma masquerading as a pancreatic head malignancy. We underscore the importance of considering extra-adrenal pheochromocytoma in the differential diagnosis of pancreatic masses, particularly when biochemical or clinical features suggest catecholamine excess.

View Article and Find Full Text PDF

Clinical presentation of pheochromocytoma and screening recommendations.

Rev Clin Esp (Barc)

January 2025

Servicio de Endocrinología y Nutrición, Hospital Universitario Ramón y Cajal, Madrid, Spain; Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain. Electronic address:

Pheochromocytomas are neuroendocrine tumors that derive from sympathetic adrenomedullary chromaffin tissue and produce catecholamines. Due to the excess release of catecholamines, they can produce arterial hypertension, tachycardia, sweating, headache and a large number of other clinical manifestations secondary to the stimulation of α and β adrenoreceptors. Screening for pheochromocytoma is recommended in patients with paroxysmal, resistant or early-onset arterial hypertension, in cases with symptoms suggestive of catecholamine hypersecretion, patients with hereditary syndromes associated with pheochromocytomas, diabetes mellitus of atypical presentation and in adrenal incidentalomas with radiological characteristics not typical of adenoma (with > 10 Hounsfield Units on non-contrast CT).

View Article and Find Full Text PDF

Quantifying urinary catecholamines and metanephrines is essential for the clinical screening and diagnosis of neuroendocrine tumours. HPLC with electrochemical detection (HPLC-ECD) is commonly used for this type of analysis but requires extensive sample cleanup. Simple and rapid dilute-and-shoot LC-multiple-reaction monitoring (MRM)-MS assays have been developed for quantitating these analytes in urine but have not yet been validated according to the Clinical and Laboratory Standards Institute (CLSI) guidelines.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!